Posted by Michael Wonder on 16 Mar 2023
Sanofi cuts US list price of Lantus, its most prescribed insulin, by 78% and caps out of pocket Lantus costs at $35 for all patients with commercial insurance
16 March 2023 - Sanofi announces that it will cut the list price of Lantus (insulin glargine injection) 100 units/mL, its most widely prescribed insulin in the US, by 78%.
The company also will establish a $35 cap on out of pocket costs for Lantus for all patients with commercial insurance, underscoring its longstanding commitment to offer affordable access to medicines.
These moves, which go into effect 1 January 2024, will come in addition to decisions taken in June 2022 to lower diabetes medicines costs: the launch of an unbranded Lantus biologic at - 60% versus Lantus list price, and a cap on out of pocket costs on insulin to $35 for all people without insurance.
